ZOMETA® RCC Patient Case Study Can Delay Time To First Pathologic Fracture

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Renal Cell Carcinoma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Renal Cell Carcinoma Patient Case Study - Carlo

Carlo V.

Aged 67 years
Retired accountant
Takes sculpting classes twice a week

Page

1 2 3

ZOMETA^® can delay time to first pathologic fracture in patients like Carlo with advanced renal cell carcinoma

Time to first pathologic fracture⁵

$Time to first pathologic fracture$

ZOMETA significantly extended median time to first pathologic fracture vs placebo (median not reached vs 168 days, P=.003)

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

ZOMETA® can delay time to first pathologic fracture in patients like Carlo with advanced renal cell carcinoma

ZOMETA^® can delay time to first pathologic fracture in patients like Carlo with advanced renal cell carcinoma